Predictive scoring system for distinguishing Stenotrophomonas maltophilia bacteremia from Pseudomonas aeruginosa bacteremia in patients with hematological malignancies
- PMID: 36971808
- DOI: 10.1007/s00277-023-05185-7
Predictive scoring system for distinguishing Stenotrophomonas maltophilia bacteremia from Pseudomonas aeruginosa bacteremia in patients with hematological malignancies
Abstract
Difficulties in immediately distinguishing Stenotrophomonas maltophilia (SM) bacteremia from Pseudomonas aeruginosa (PA) bacteremia in the clinical setting can lead to treatment delay. We aimed to develop a scoring system to immediately distinguish SM bacteremia from PA bacteremia using clinical indicators. We enrolled cases of SM and PA bacteremia in adult patients with hematological malignancies between January 2011 and June 2018. The patients were randomized into derivation and validation cohorts (2:1), and a clinical prediction tool for SM bacteremia was developed and verified. In total, 88 SM and 85 PA bacteremia cases were identified. In the derivation cohort, the following independent predictors of SM bacteremia were identified: no evidence of PA colonization, antipseudomonal β-lactam breakthrough bacteremia, and central venous catheter insertion. We scored each of the three predictors according to their regression coefficient (2, 2, and 1, respectively). Receiver operating characteristic curve analysis confirmed the score's predictive performance, with an area under the curve of 0.805. The combined sensitivity and specificity (0.655 and 0.821) was highest with a cut-off value of 4 points. Positive and negative predictive values were 79.2% (19/24) and 69.7% (23/33), respectively. This novel predictive scoring system is potentially useful for distinguishing SM bacteremia from PA bacteremia, which would facilitate immediate administration of appropriate antimicrobial therapy.
Keywords: Bloodstream infection; Hematological malignancies; Predictive scoring system; Pseudomonas aeruginosa; Stenotrophomonas maltophilia.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains.BMC Infect Dis. 2019 Aug 28;19(1):754. doi: 10.1186/s12879-019-4394-4. BMC Infect Dis. 2019. PMID: 31462215 Free PMC article.
-
Clinical predictors of Stenotrophomonas maltophilia bacteremia in adult patients with hematologic malignancy.Ann Hematol. 2018 Feb;97(2):343-350. doi: 10.1007/s00277-017-3178-4. Epub 2017 Nov 14. Ann Hematol. 2018. PMID: 29138886
-
Characteristics of Stenotrophomonas maltophilia bacteremia in children.Pediatr Int. 2016 Feb;58(2):113-8. doi: 10.1111/ped.12745. Epub 2015 Nov 5. Pediatr Int. 2016. PMID: 26139084
-
Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.Antimicrob Agents Chemother. 2016 Oct 21;60(11):6673-6678. doi: 10.1128/AAC.00984-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27572416 Free PMC article.
-
Risk factors for mortality in Stenotrophomonas maltophilia bacteremia - a meta-analysis.Infect Dis (Lond). 2024 May;56(5):335-347. doi: 10.1080/23744235.2024.2324365. Epub 2024 Mar 4. Infect Dis (Lond). 2024. PMID: 38436567 Review.
Cited by
-
Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population.Ann Hematol. 2024 May;103(5):1745-1752. doi: 10.1007/s00277-024-05686-z. Epub 2024 Mar 8. Ann Hematol. 2024. PMID: 38453704 Free PMC article.
-
Cefiderocol susceptibility of 146 Stenotrophomonas maltophilia strains clinically isolated from blood in two Japanese hospitals over a 10-year period.Eur J Clin Microbiol Infect Dis. 2024 Dec;43(12):2485-2488. doi: 10.1007/s10096-024-04960-2. Epub 2024 Oct 11. Eur J Clin Microbiol Infect Dis. 2024. PMID: 39392554
References
-
- Araoka H, Baba M, Yoneyama A (2010) Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis 29(5):605–608. https://doi.org/10.1007/s10096-010-0882-6 - DOI - PubMed
-
- Kim EJ, Kim YC, Ahn JY, Jeong SJ, Ku NS, Choi JY et al (2019) Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis 19(1):754. https://doi.org/10.1186/s12879-019-4394-4 - DOI - PubMed - PMC
-
- Bao H, Qiao Y, Liu D, Chen J, Wu X, Hu X et al (2020) The clinical impact of Stenotrophomonas maltophilia bacteremia on the 30-day mortality rate in patients with hematologic disorders: a single-institution experience. Infection 48(2):205–212. https://doi.org/10.1007/s15010-019-01369-4 - DOI - PubMed
-
- Looney WJ, Narita M, Mühlemann K (2009) Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 9(5):312–323. https://doi.org/10.1016/s1473-3099(09)70083-0 - DOI - PubMed
-
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52(4):e56-93. https://doi.org/10.1093/cid/cir073 - DOI
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources